Semaglutide mastery course
Unit 6 of 12
Cardiovascular outcomes
Lowering glucose or weight is a surrogate; preventing heart attacks is the real prize. Semaglutide cleared that bar in…
From surrogate markers to hard heart outcomes
Lowering glucose or weight is a surrogate; preventing heart attacks is the real prize. Semaglutide cleared that bar in dedicated outcome trials. SUSTAIN-6 showed reduced major cardiovascular events in type 2 diabetes, and SELECT extended the benefit to obesity without diabetes.
This unit reads those forest-plot results carefully, including the retinopathy caution from SUSTAIN-6, so the cardiovascular story stays honest about both benefit and risk.